ACADIA Pharmaceuticals Inc (ACAD) — Capital Reinvestment Ratio
Latest as of March 2026:
0.15x
ACADIA Pharmaceuticals Inc (ACAD) has a Capital Reinvestment Ratio of 0.15x as of March 2026, meaning it reinvests 0% of its operating cash flow ($33.98 Million) in capital expenditures ($5.21 Million). See ACAD cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.15x
Capex / Operating Cash Flow
Operating Cash Flow
$33.98 Million
USD
Capital Expenditures
$5.21 Million
USD
Data as of
Mar 2026
Most recent filing
ACADIA Pharmaceuticals Inc Capital Reinvestment Ratio (2023–2025)
This chart tracks ACADIA Pharmaceuticals Inc's Capital Reinvestment Ratio across 3 annual periods.
Annual Capital Reinvestment Ratio for ACADIA Pharmaceuticals Inc (2023–2025)
Year-by-year Capital Reinvestment Ratio for ACADIA Pharmaceuticals Inc from 2023 to 2025. For live market cap and broader valuation context, see ACADIA Pharmaceuticals Inc (ACAD) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.04x | $109.84 Million | $4.69 Million | ▲ +1187.7% |
| 2024 | 0.00x | $157.72 Million | $523.00K | ▼ -99.9% |
| 2023 | 2.40x | $16.70 Million | $40.05 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow